Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antitumor, monoclonal antibodies | 5777 | None |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Linvoseltamab-gcpt is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In vitro, linvoseltamab-gcpt activated T-cells, caused the release of various proinflammatory cytokines, and resulted in the lysis of multiple myeloma cells. Linvoseltamab-gcpt had anti-tumor activity in mouse models of multiple myeloma.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 23, 2025 | EMA | Regeneron Ireland Designated Activity Company (DAC) | |
| July 2, 2025 | FDA | RENGENERON PHARMACEUTICALS, INC. |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | L01FX37 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES Other monoclonal antibodies and antibody drug conjugates |
| FDA PE | N0000009267 | Increased Cytokine Activity |
| MeSH PA | D000074322 | Antineoplastic Agents, Immunological |
| MeSH PA | D000970 | Antineoplastic Agents |
| FDA MoA | N0000175617 | CD3-directed Antibody Interactions |
| FDA MoA | N0000175618 | CD3 Receptor Agonists |
| FDA MoA | N0000194165 | B Cell Maturation Antigen-directed Antibody Interactions |
| FDA EPC | N0000194166 | Bispecific B Cell Maturation Antigen-directed CD3 T Cell Engager |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Relapsed or refractory multiple myeloma | indication | 109989006 | DOID:9538 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| T-cell surface glycoprotein CD3 | Surface antigen | BINDING AGENT | EC50 | 6.81 | DRUG LABEL | DRUG LABEL | |||
| Tumor necrosis factor receptor superfamily member 17 | Tumour-associated antigen | BINDING AGENT | Kd | 0.44 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| 2408319-25-3 | SECONDARY_CAS_RN |
| CHEMBL5095373 | ChEMBL_ID |
| C000731817 | MESH_SUPPLEMENTAL_RECORD_UI |
| 13305 | IUPHAR_LIGAND_ID |
| 4044097 | VANDF |
| 4044098 | VANDF |
| C5667182 | UMLSCUI |
| CHEBI:758940 | CHEBI |
| 12104 | INN_ID |
| D12222 | KEGG_DRUG |
| 396209 | MMSL |
| 44236 | MMSL |
| d10292 | MMSL |
| 020153 | NDDF |
| M3CPC50MZS | UNII |
| 2719416 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| LYNOZYFIC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61755-054 | INJECTION, SOLUTION, CONCENTRATE | 5 mg | INTRAVENOUS | BLA | 30 sections |
| LYNOZYFIC | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61755-056 | INJECTION, SOLUTION, CONCENTRATE | 200 mg | INTRAVENOUS | BLA | 30 sections |